This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 45/6/1200    most recent 01.HYP.0000165674.58470.8fv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Klöss, S. Articles by Mülsch, A. Search for Related Content PubMed PubMed Citation Articles by Klöss, S. Articles by Mülsch, A. Related Collections Other hypertension Gene expression Gene regulation Hypertension - basic studies Endothelium/vascular type/nitric oxide Other Vascular biology Related Article

(Hypertension. 2005;45:1200.)
© 2005 American Heart Association, Inc.

Original Articles

Human-Antigen R (HuR) Expression in Hypertension

Downregulation of the mRNA Stabilizing Protein HuR in Genetic Hypertension

Stephan Klöss; Daniela Rodenbach; Reingart Bordel; Alexander Mülsch

From the Physiologisches Institut II, Johann Wolfgang Goethe-Universität, Frankfurt/Main, Germany. A.M.’s present address: II. Medizinische Klinik u. Poliklinik, Klinikum der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, D-55131 Mainz, Germany.

Reprint requests to Stephan Klöss, Institut für Physiologie II/AG Backus, Universität Frankfurt; Theodor-Stern-Kai 7, Haus 26/3.OG, D-60596 Frankfurt, Germany. E-mail S.Kloess{at}em.uni-frankfurt.de

In aged spontaneously hypertensive rats (SHR), vasorelaxant responses to NO are attenuated compared with normotensive control rats (Wistar-Kyoto [WKY]) because of a decreased expression of the important NO receptor soluble guanylyl cyclase (sGC). Because the expression of sGC subunits ₁ and ß₁ is controlled at the post-transcriptional level by the mRNA-binding protein human-antigen R (HuR), we now assessed whether or not altered expression of HuR could account for downregulation of sGC₁ and sGCß₁ in genetic hypertension. The expression of HuR (and sGC₁ and sGCß₁) in aortas from aged SHR was significantly decreased at the mRNA and protein level compared with age-matched WKY rats, whereas expression of HuR was not different in prehypertensive young (2 months of age) SHR and age-matched WKY rats. The mRNA-binding activity of HuR in native aortic protein extracts from aged SHR was markedly reduced compared with normotensive WKY rats, as detected by RNA electrophoretic mobility shift analysis, using biotin-labeled adenine and uracil (AU)–rich element (ARE)–containing RNA probes from the 3'-untranslated region of sGC₁ and sGCß₁. In contrast, ARE-binding activity was not different between prehypertensive young SHR and young WKY rats. In vitro RNA degradation assays using the same AU-rich sGC mRNA probes revealed an accelerated sGC₁ and sGCß₁ mRNA decay in the presence of native protein extract from hypertensive SHR, which was less rapid with aortic protein from normotensive WKY rats. These findings suggest that in this animal model of genetic hypertension, the reduced expression of sGC subunits is mediated by downregulation of the sGC mRNA–stabilizing protein HuR.

Key Words: rats, spontaneously hypertensive • aorta • gene regulation • hypertension, genetic

Related Article:

Loss of Vascular Regulation by Soluble Guanylate Cyclase Is Emerging as a Key Target of the Hypertensive Disease Process

Michael S. Wolin
Hypertension 2005 45: 1068-1069. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				S. de Frutos, C. H. Nitta, E. Caldwell, J. Friedman, and L. V. Gonzalez Bosc Regulation of soluble guanylyl cyclase-{alpha}1 expression in chronic hypoxia-induced pulmonary hypertension: role of NFATc3 and HuR Am J Physiol Lung Cell Mol Physiol, September 1, 2009; 297(3): L475 - L486. [Abstract] [Full Text] [PDF]

				B. Fisslthaler and I. Fleming Activation and Signaling by the AMP-Activated Protein Kinase in Endothelial Cells Circ. Res., July 17, 2009; 105(2): 114 - 127. [Abstract] [Full Text] [PDF]

				J. Ren, Z. Mi, N. A. Stewart, and E. K. Jackson Identification and Quantification of 2',3'-cAMP Release by the Kidney J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 855 - 865. [Abstract] [Full Text] [PDF]

				I. G. Sharina, F. Jelen, E. P. Bogatenkova, A. Thomas, E. Martin, and F. Murad {alpha}1 Soluble Guanylyl Cyclase (sGC) Splice Forms as Potential Regulators of Human sGC Activity J. Biol. Chem., May 30, 2008; 283(22): 15104 - 15113. [Abstract] [Full Text] [PDF]

				K. S. Murthy Inhibitory Phosphorylation of Soluble Guanylyl Cyclase by Muscarinic m2 Receptors via G{beta}{gamma}-Dependent Activation of c-Src Kinase J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 183 - 189. [Abstract] [Full Text] [PDF]

				J. P. Cabilla, M. d. C. Diaz, L. I. Machiavelli, A. H. Poliandri, F. A. Quinteros, M. Lasaga, and B. H. Duvilanski 17{beta}-Estradiol Modifies Nitric Oxide-Sensitive Guanylyl Cyclase Expression and Down-Regulates Its Activity in Rat Anterior Pituitary Gland Endocrinology, September 1, 2006; 147(9): 4311 - 4318. [Abstract] [Full Text] [PDF]